Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;15(2):81-85.
doi: 10.2174/1875692115666170815161754.

Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review

Jesus Rodriguez-Pascual  1 , Antonio Cubillo  1
Affiliations
Review

Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review

Jesus Rodriguez-Pascual et al. Curr Pharmacogenomics Person Med. 2017 Dec.

Abstract

Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body.

Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.

Keywords: Colorectal cancer; angiogenesis; bevacizumab; biomarkers; chemotherapy; metastatic disease.

PubMed Disclaimer

References

    1. International Agency for Research on Cancer 2015 http://globocan.iarc.fr/Pages/fact_sheets_
    1. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997;18:4–25. - PubMed
    1. Lee J.C., Chow N.H., Wang S.T., et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer. 2000;36:748–753. - PubMed
    1. Giantonio B.J., Levy D.E., O’dwyer P.J., et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: Results from the Eastern cooperative oncology group study E2200. Ann. Oncol. 2006;17:1399–1403. - PubMed
    1. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. (Berl.) 1999;77:527–543. - PubMed

LinkOut - more resources